Get the data you need to support your best clinical decision making.
421+
Korem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis.
421+
Korem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis.
421+
Korem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis.
421+
Korem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis.
CancerVision provides broader insight than many conventional genetic tests and reduces the likelihood of false positives by ruling out benign variants in the tumor sample.
CancerVision is a whole genome sequencing test for patients with solid tumors that may have been recently diagnosed, are recurring or metastatic, or aren’t responding to treatment. It is also for patients who want to find more answers about the genetic drivers of their cancer. We offer you and your patients whole genome coverage, actionable findings, clinical trial matching and expert support to provide the best care possible.
Our goal is to be a resource for you beyond top-tier genetic testing. We’re here to provide and translate complex data and findings to turn them into actionable insights to support your patients.
CancerVision has been clinically validated and detected 100% of the variants1 identified by the clinically validated TruSight Oncology 500 (Illumina) NGS target oncology panel test. Additionally, CancerVision distinguished between germline and somatic variants. Understanding the origin of the mutation is critical in choosing the most effective treatment options.
Whole genome sequencing finds more complex changes within the genome. For example, CancerVision is able to detect accurate genomic pattern-based markers and provides highly accurate HRD detection – without adding any other tests (688 cancer patient cases).
Our proprietary high-performing bioinformatics algorithm thoroughly analyzes a patient’s genome data and highlights the findings highly relevant to clinical utility. In one study, more than 70%2 of our WGS reports yielded clinically relevant insights, including actionability for therapeutic options and clinical clarity.
Ordering a test is quick and easy in our provider order portal.
Start an online order by filling out the test requisition form. We will send our kits to your office.
Use our supplied sample collection kit and instructions to collect samples for testing.
Ship the samples directly to us.
Receive the test results via email and fax. You can also access to all test results you ordered in our online portal.
10 FFPE from curls or slides, with an H&E stained slide for reference
10mL peripheral blood, or
previously extracted DNA from a CLIA certified laboratory
2 weeks from receipt of patient samples at our lab
If you don’t see your question answered here, please contact us at inquiry@inocras.com.
To order a test, please sign up and complete the online test requisition form. Our sales representatives will follow up with you shortly.
Our tests are not currently covered by insurance. Upon ordering, your patient will receive an invoice for which payment will be required directly from the patient’s out-of-pocket expenses.
You can access Inocras test reports as soon as they are ready via our digital provider order portal. You can also receive access to results via secure email or request to have results faxed to you.
You’ll have access to our team of in-house medical experts, researchers, and genomic scientists who can explain the results to you and answer any questions. If you have questions about a patient’s results, you can email us at inquiry@inocras.com for support. One of our experts will respond to your questions or set up time to speak with you.